Company profile: Unity Biotechnology
1.1 - Company Overview
Company description
- Provider of therapeutics to prevent, halt, and reverse diseases of aging, with candidates for age-related eye diseases and neurodegeneration: UBX1325, a Bcl-xL inhibitor in clinical development that selectively eliminates senescent cells in diseased vasculature for conditions including diabetic macular edema; UBX2050, an investigational Tie2-activating monoclonal antibody; and UBX2089, a recombinant α-Klotho protein.
Products and services
- UBX2089: A recombinant α-Klotho protein being explored for cognitive enhancement and potential treatment of neurodegenerative diseases associated with aging
- UBX2050: An investigational Tie2-activating monoclonal antibody designed to restore Tie2 function and promote healthy vasculature in age-related eye diseases
- UBX1325: A clinical-stage Bcl-xL inhibitor for age-related eye diseases, including diabetic macular edema, that selectively eliminates senescent cells within diseased vasculature
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Unity Biotechnology
Inivata
HQ: United States
Website
- Description: Provider of clinical cancer genomics and liquid biopsy solutions using circulating tumor DNA (ctDNA) to improve testing and treatment. Offers assays and NGS profiles for lung and myeloid cancers, including InVisionFirst-Lung, NeoTYPE DNA & RNA - Lung, Neo Comprehensive - Myeloid Disorders, and an early-stage NSCLC panel, plus NeoSeek for biomarker cohort analysis and NeoAccess for streamlined test ordering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inivata company profile →
Noviogendix
HQ: The Netherlands
Website
- Description: Provider of molecular diagnostics and services for physicians, clinics, and hospitals, focused on developing a non-invasive liquid biopsy test for prostate cancer, leveraging an expert-based, integrated approach to create advanced, clinically useful molecular diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noviogendix company profile →
Biological Dynamics
HQ: United States
Website
- Description: Provider of next-gen liquid biopsy solutions using a true multiomics approach to detect early cancer in blood; offers the ExoVerita Pro system and platform for automated exosome isolation via alternating current electrokinetics; develops exosome- and proteomics-based diagnostic assays; leads ExoLuminate pancreatic cancer study; and runs a Technology Access Program offering partners access to Biological Dynamics' system for diagnostic solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biological Dynamics company profile →
Solid Biosciences
HQ: United States
Website
- Description: Provider of gene therapy candidates and research focused on rare genetic diseases, including SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Solid Biosciences company profile →
Microbiotica
HQ: United Kingdom
Website
- Description: Provider of human microbiome therapeutics and biomarkers, offering live bacterial therapeutics that engraft in the intestine; microbiome-based biomarkers for drug response, side-effects, or disease progression to stratify patients; a gut bacteria Culture Collection and proprietary Reference Genome Database; advanced microbiome bioinformatics and machine learning; and Personalised Bacterial Banks.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microbiotica company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Unity Biotechnology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Unity Biotechnology
2.2 - Growth funds investing in similar companies to Unity Biotechnology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Unity Biotechnology
4.2 - Public trading comparable groups for Unity Biotechnology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →